Not all sufferers with CLL call for therapy. Inspite of all recent developments, the iwCLL nevertheless suggests watchful observation for clients with asymptomatic disorder.86 This advice relies on a minimum of two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Deep,